

Authorization Page
Generated on June 23, 2015 1:08PM
TEMPORARY ADMINISTRATIVE RULES

Oregon Health Authority, Division of Medical Assistance
Programs

410

Agency and Division

Administrative Rules Chapter Number

Sandy Cafourek

dmap.rules@state.or.us

Rules Coordinator

Email Address

500 Summer St. NE, Salem, OR 97301

503-945-6430

Address

Telephone

Upon filing.

Adopted on

07/01/2015 thru 12/27/2015

Effective dates

RULE CAPTION

Preferred Drug List March 26, 2015 DUR/P&T Action.

Not more than 15 words

RULEMAKING ACTION

ADOPT:

AMEND: 410-121-0030

SUSPEND:

Stat. Auth.: ORS 413.032, 413.042, 414.065, 414.325, 414.330 to 414.414, 414.312, and 414.316

Other Auth.:

Stats. Implemented: ORS 414.065; 414.325, 414.334, 414.361, 414.369, 414.371, 414.353, and 414.354

RULE SUMMARY

The Pharmaceutical Services program administrative rules (Division 121) govern Division payments for services provided to certain clients. The Division needs to amend rules as follows:

410-121-0030:

Preferred:

Viekiera Pakā,¢

Laxative drug class
Polyethylene glycol 3350
Lactulose
Senna products
Bulk forming laxatives less than \$1/unit
Osmotic laxatives less than \$1/unit
Surfactant, stimulant, and saline laxatives
Isosorbide dinitrate - capsule ER
Nitroglycerin - capsule ER
Adalimumab (Humira Pediatric Crohn'sâ„†)
Calcium Citrate - tablet
Buprenorphine HCL / Naloxone HCL
Dexmethylphenidate HCL
Chlorpromazine HCL
Fluphenazine HCL

Non-Preferred:

Bulk forming laxatives \$1/unit or more
Osmotic laxatives \$1/unit or more
Lubricant laxatives
Cimetidine - tablet
Spinosad

Clerical - Various clerical changes were made to system class, drug and form names.

STATEMENT OF NEED AND JUSTIFICATION

The amendment of OAR 410-121-0030

In the Matter of

OR Law 2011, chapter 720 (HB 2100):
http://www.oregon.gov/pers/docs/2011_legislation/hb2100.en.pdf

Documents Relied Upon, and where they are available

The Pharmaceutical Services program administrative rules (division 121) govern Division payments for services provided to certain clients. The Division temporarily amended 410-121-0030 per the Drug Use Review (DUR) Pharmacy & Therapeutics (P&T) Committee's recommendations made during the March 26, 2015 meeting. The Authority needs to implement changes to the Preferred Drug List to ensure the safe and appropriate use of cost effective prescription drugs for the Oregon Health Plan's fee-for-service recipients.

410-121-0030:

Preferred:

Viekiera Pakâ„†

Laxative drug class

Polyethylene glycol 3350

Lactulose
Senna products
Bulk forming laxatives less than \$1/unit
Osmotic laxatives less than \$1/unit
Surfactant, stimulant, and saline laxatives
Isosorbide dinitrate - capsule ER
Nitroglycerin - capsule ER
Adalimumab (Humira Pediatric Crohn'sâ„†)

Calcium Citrate - tablet
Buprenorphine HCL / Naloxone HCL
Dexmethylphenidate HCL
Chlorpromazine HCL
Fluphenazine HCL

Non-Preferred:


Bulk forming laxatives \$1/unit or more
Osmotic laxatives \$1/unit or more
Lubricant laxatives
Cimetidine - tablet
Spinosad

Clerical - Various clerical changes were made to system class, drug and form names.

Need for the Temporary Rule(s)

The Authority finds that failure to act promptly will result in serious prejudice to the public interest, the Authority, and clients enrolled in Oregon's Medicaid program by delaying the reassessment and update of preferred drug lists and prior authorization requirements. These rules need to be adopted promptly so the Authority can ensure the safe and appropriate use of Medicaid covered drugs.

Justification of Temporary Rules



Authorized Signer

DAVID SIMMITT

Printed Name

6/30/2015

Date

Authorization Page replaces the ink signature on paper filings. Have your authorized signer sign and date, then scan and attach it to your filing. You must complete this step before submitting your Permanent and Temporary filings.

Secretary of State
STATEMENT OF NEED AND JUSTIFICATION

A Certificate and Order for Filing Temporary Administrative Rules accompanies this form.

Oregon Health Authority, Division of Medical Assistance Programs

410

Agency and Division

Administrative Rules Chapter Number

In the Matter of: The amendment of OAR 410-121-0030

Rule Caption: Preferred Drug List–March 26, 2015 DUR/P&T Action

Statutory Authority: ORS 413.032, 413.042, 414.065, 414.325, 414.330 to 414.414, 414.312, 414.316

Other Authority: None

Stats. Implemented: ORS 414.065; 414.325, 414.334, 414.361, 414.369, 414.371, 414.353, 414.354

Need for the Temporary Rule(s): The Pharmaceutical Services program administrative rules (division 121) govern Division payments for services provided to certain clients. The Division temporarily amended 410-121-0030 per the Drug Use Review (DUR) Pharmacy & Therapeutics (P&T) Committee's recommendations made during the March 26, 2015 meeting. The Authority needs to implement changes to the Preferred Drug List to ensure the safe and appropriate use of cost effective prescription drugs for the Oregon Health Plan's fee-for-service recipients.

410-121-0030:

Preferred:

Viekiera Pak™

Laxative drug class

 Polyethylene glycol 3350

 Lactulose

 Senna products

 Bulk forming laxatives less than \$1/unit

 Osmotic laxatives less than \$1/unit

 Surfactant, stimulant, and saline laxatives

Isosorbide dinitrate – capsule ER

Nitroglycerin – capsule ER

Adalimumab (Humira Pediatric Crohn's™)

Calcium Citrate – tablet

Buprenorphine HCL / Naloxone HCL

Dexmethylphenidate HCL

Chlorpromazine HCL

Fluphenazine HCL

Non-Preferred:

Bulk forming laxatives \$1/unit or more

Osmotic laxatives \$1/unit or more

Lubricant laxatives

Cimetidine – tablet

Spinosad

Clerical - Various clerical changes were made to system class, drug and form names.

Documents Relied Upon, and where they are available: OR Law 2011, chapter 720 (HB 2100):
http://www.oregon.gov/pers/docs/2011_legislation/hb2100.en.pdf

Justification of Temporary Rule(s): The Authority finds that failure to act promptly will result in serious prejudice to the public interest, the Authority, and clients enrolled in Oregon's Medicaid program by delaying the reassessment and update of preferred drug lists and prior authorization requirements. These rules need to be adopted promptly so the Authority can ensure the safe and appropriate use of Medicaid covered drugs.


Authorized Signer

DAVID SUMMIT
Printed name

6/20/2015
Date

Administrative Rules Unit, Archives Division, Secretary of State, 800 Summer Street NE, Salem, Oregon 97310.

410-121-0030

Practitioner-Managed Prescription Drug Plan

(1) The Practitioner-Managed Prescription Drug Plan (PMPDP) is a plan that ensures that OHP fee-for-service clients have access to the most effective prescription drugs appropriate for their clinical conditions at the best possible price:

(a) Licensed health care practitioners, who are informed by the latest peer reviewed research, make decisions concerning the clinical effectiveness of the prescription drugs;

(b) Licensed health care practitioners also consider the client's health condition, personal characteristics, and the client's gender, race, or ethnicity.

(2) PMPDP Preferred Drug List (PDL):

(a) The PDL is the primary tool the Division uses to inform licensed health care practitioners about the results of the latest peer-reviewed research and cost effectiveness of prescription drugs;

(b) The PDL contains a list of prescription drugs that the Division, in consultation with the Drug Use Review (DUR)/Pharmacy & Therapeutics Committee (P&T), has determined represent the most effective drugs available at the best possible price;

(c) The PDL shall include drugs that are Medicaid reimbursable and the Food and Drug Administration (FDA) has determined to be safe and effective.

(3) PMPDP PDL Selection Process:

(a) The Division shall utilize the recommendations made by the P&T that result from an evidence-based evaluation process as the basis for selecting the most effective drugs;

(b) The Division shall ensure the drugs selected in section (3)(a) that are available for the best possible price and shall consider any input from the P&T about other FDA-approved drugs in the same class that are available for a lesser relative price. The Division shall determine relative price using the methodology described in section (4);

(c) The Division shall evaluate selected drugs for the drug classes periodically:

(A) The Division may evaluate –more frequently if new safety information or the release of new drugs in a class or other information makes an evaluation advisable;

(B) New drugs in classes already evaluated for the PDL shall be non-preferred until the new drug has been reviewed by the P&T;

(C) The Division shall make all revisions to the PDL using the rulemaking process and shall publish the changes on the Division's Pharmaceutical Services provider rules website.

(4) Relative cost and best possible price determination:

(a) The Division shall determine the relative cost of all drugs in each selected class that are Medicaid reimbursable and that the FDA has determined to be safe and effective;

(b) The Division may also consider dosing issues, patterns of use, and compliance issues. The Division shall weigh these factors with any advice provided by the P&T in reaching a final decision.

(5) Pharmacy providers shall dispense prescriptions in the generic form unless:

(a) The practitioner requests otherwise pursuant to OAR 410-121-0155;

(b) The brand name medication is listed as preferred on the PDL.

(6) The exception process for obtaining non-preferred physical health drugs that are not on the PDL drugs shall be as follows:

(a) If the prescribing practitioner in their professional judgment wishes to prescribe a physical health drug not on the PDL, they may request an exception subject to the requirements of OAR 410-121-0040;

(b) The prescribing practitioner must request an exception for physical health drugs not listed in the PDL subject to the requirements of OAR 410-121-0060;

(c) Exceptions shall be granted when:

(A) The prescriber in their professional judgment determines the non-preferred drug is medically appropriate after consulting with the Division or the Oregon Pharmacy Call Center; or

(B) Where the prescriber requests an exception subject to the requirement of section (6)(b) and fails to receive a report of PA status within 24 hours, subject to OAR 410-121-0060.

(7) Table 121-0030-1, PMPDP PDL dated ~~April 18~~July 1, 2015 is adopted and incorporated by reference and is found at: www.orpdl.org.

Stat. Auth.: ORS 413.032, 413.042, 414.065, 414.325, 414.330 to 414.414, 414.312, 414.316

Stats. Implemented: ORS 414.065; 414.325, 414.334, 414.361, 414.369, 414.371, 414.353, 414.354